Latest News for DSS
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) today announced that it has withdrawn its previously filed Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission. After careful review of current market conditions and deal terms, management and the Board of Directors concluded that proceeding with the offering at this time would not reflect the value DSS…
ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration has accepte
ROCHESTER, N.Y., May 08, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) announced that its annual report (10-K) for the fiscal year ending December 31, 2025, filed on March 31, 2026, includes an audit opinion from HTL International LLC. that contains a "going concern" qualification. This announcement is made pursuant to NYSE American LLC Company Guide Section 610(b), which requires public announcement of…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DSS.
U.S. House Trading
No House trades found for DSS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.